BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Huang X, Zhang G, Tang T, Liang T. Identification of tumor antigens and immune subtypes of pancreatic adenocarcinoma for mRNA vaccine development. Mol Cancer 2021;20:44. [PMID: 33648511 DOI: 10.1186/s12943-021-01310-0] [Cited by in Crossref: 41] [Cited by in F6Publishing: 44] [Article Influence: 41.0] [Reference Citation Analysis]
Number Citing Articles
1 Liu W, Quan B, Li M, Zhang F, Hu K, Yin X. PVR—A Prognostic Biomarker Correlated with Immune Cell Infiltration in Hepatocellular Carcinoma. Diagnostics 2022;12:2953. [DOI: 10.3390/diagnostics12122953] [Reference Citation Analysis]
2 Kadasah SF. Establishment and Systematic Evaluation of Gastric Cancer Classification Model Based on Pyroptosis. Diagnostics 2022;12:2858. [DOI: 10.3390/diagnostics12112858] [Reference Citation Analysis]
3 Chen Y, Jiang N, Chen M, Sui B, Liu X. Identification of tumor antigens and immune subtypes in head and neck squamous cell carcinoma for mRNA vaccine development. Front Cell Dev Biol 2022;10. [DOI: 10.3389/fcell.2022.1064754] [Reference Citation Analysis]
4 Zhu Y, Zheng J, Jia Q, Duan Z, Yao H, Yang J, Sun Y, Jiang S, Liu D, Huo Y. Immunosuppression, immune escape, and immunotherapy in pancreatic cancer: focused on the tumor microenvironment. Cell Oncol 2022. [DOI: 10.1007/s13402-022-00741-1] [Reference Citation Analysis]
5 Huang X, Zhang G, Tang TY, Gao X, Liang TB. Personalized pancreatic cancer therapy: from the perspective of mRNA vaccine. Mil Med Res 2022;9:53. [PMID: 36224645 DOI: 10.1186/s40779-022-00416-w] [Reference Citation Analysis]
6 Li S, Zhang Q, Weng L, Li J. Construction of an immune-related signature for predicting the ischemic events in patients undergoing carotid endarterectomy. Front Genet 2022;13:1014264. [DOI: 10.3389/fgene.2022.1014264] [Reference Citation Analysis]
7 Weng W, Yu L, Li Z, Tan C, Lv J, Lao IW, Hu W, Deng Z, Liu Z, Wang J, Xu M. The immune subtypes and landscape of sarcomas. BMC Immunol 2022;23. [DOI: 10.1186/s12865-022-00522-3] [Reference Citation Analysis]
8 Turpin A, Neuzillet C, Colle E, Dusetti N, Nicolle R, Cros J, de Mestier L, Bachet JB, Hammel P. Therapeutic advances in metastatic pancreatic cancer: a focus on targeted therapies. Ther Adv Med Oncol 2022;14:17588359221118019. [PMID: 36090800 DOI: 10.1177/17588359221118019] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Hou X, Chen C, Lan X, He X. Unveiling the molecular features, relevant immune and clinical characteristics of SIGLEC15 in thyroid cancer. Front Immunol 2022;13:975787. [DOI: 10.3389/fimmu.2022.975787] [Reference Citation Analysis]
10 Zhang M, Shi M, Yu Y, Sang J, Wang H, Shi J, Duan P, Ge R. The Immune Subtypes and Landscape of Advanced-Stage Ovarian Cancer. Vaccines (Basel) 2022;10:1451. [PMID: 36146529 DOI: 10.3390/vaccines10091451] [Reference Citation Analysis]
11 Gu Y, Duan J, Yang N, Yang Y, Zhao X. mRNA vaccines in the prevention and treatment of diseases. MedComm 2022;3. [DOI: 10.1002/mco2.167] [Reference Citation Analysis]
12 Rubin SJS, Sojwal RS, Gubatan J, Rogalla S. The Tumor Immune Microenvironment in Pancreatic Ductal Adenocarcinoma: Neither Hot nor Cold. Cancers 2022;14:4236. [DOI: 10.3390/cancers14174236] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Liao W, Shi Z, Tang H, Wu T, Zhang C, He Y, Zou R, Wang L, Zhang Z. Identifying Potential Tumor Antigens and Antigens-Related Subtypes in Hepatocellular Carcinoma for mRNA Vaccine Development. Journal of Oncology 2022;2022:1-12. [DOI: 10.1155/2022/6851026] [Reference Citation Analysis]
14 Noubissi Nzeteu GA, Gibbs BF, Kotnik N, Troja A, Bockhorn M, Meyer NH. Nanoparticle-based immunotherapy of pancreatic cancer. Front Mol Biosci 2022;9:948898. [DOI: 10.3389/fmolb.2022.948898] [Reference Citation Analysis]
15 Fu J, Chen F, Lin Y, Gao J, Chen A, Yang J. Discovery and characterization of tumor antigens in hepatocellular carcinoma for mRNA vaccine development. J Cancer Res Clin Oncol 2022. [PMID: 36038676 DOI: 10.1007/s00432-022-04325-2] [Reference Citation Analysis]
16 Huang T, Peng L, Han Y, Wang D, He X, Wang J, Ou C. Lipid nanoparticle-based mRNA vaccines in cancers: Current advances and future prospects. Front Immunol 2022;13:922301. [DOI: 10.3389/fimmu.2022.922301] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Ledenko M, Antwi SO, Arima S, Driscoll J, Furuse J, Klümpen H, Larsen FO, Lau DK, Maderer A, Markussen A, Moehler M, Nooijen LE, Shaib WL, Tebbutt NC, André T, Ueno M, Woodford R, Yoo C, Zalupski MM, Patel T. Sex-related disparities in outcomes of cholangiocarcinoma patients in treatment trials. Front Oncol 2022;12:963753. [DOI: 10.3389/fonc.2022.963753] [Reference Citation Analysis]
18 Jiang S, Ding X, Wu Q, Cheng T, Xu M, Huang J. Identifying immune cells-related phenotype to predict immunotherapy and clinical outcome in gastric cancer. Front Immunol 2022;13:980986. [DOI: 10.3389/fimmu.2022.980986] [Reference Citation Analysis]
19 Wang S, Yang Y, Li L, Ma P, Jiang Y, Ge M, Yu Y, Huang H, Fang Y, Jiang N, Miao H, Guo H, Yan L, Ren Y, Sun L, Zha Y, Li N. Identification of Tumor Antigens and Immune Subtypes of Malignant Mesothelioma for mRNA Vaccine Development. Vaccines (Basel) 2022;10:1168. [PMID: 35893817 DOI: 10.3390/vaccines10081168] [Reference Citation Analysis]
20 Wu C, Qin C, Long W, Wang X, Xiao K, Liu Q. Tumor antigens and immune subtypes of glioblastoma: the fundamentals of mRNA vaccine and individualized immunotherapy development. J Big Data 2022;9:92. [PMID: 35855914 DOI: 10.1186/s40537-022-00643-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
21 Zhang S, Li S, Wei Y, Xiong Y, Liu Q, Hu Z, Zeng Z, Tang F, Ouyang Y. Identification of Potential Antigens for Developing mRNA Vaccine for Immunologically Cold Mesothelioma. Front Cell Dev Biol 2022;10:879278. [DOI: 10.3389/fcell.2022.879278] [Reference Citation Analysis]
22 Ge W, Ma J, Mao T, Xu H, Zhang X, Li S, Wang Y, Yao J, Yue M, Jiao F, Wang Y, Zhuo M, Han T, Hu J, Zhang X, Cui J, Wang L. Distinguishable Prognostic Signatures and Tumor Immunogenicity Between Pancreatic Head Cancer and Pancreatic Body/Tail Cancer. Front Oncol 2022;12:890715. [PMID: 35756644 DOI: 10.3389/fonc.2022.890715] [Reference Citation Analysis]
23 Lu T, Xu R, Wang C, Zhao J, Peng B, Wang J, Zhang L. Identification of Tumor Antigens and Immune Subtypes of Esophageal Squamous Cell Carcinoma for mRNA Vaccine Development. Front Genet 2022;13:853113. [DOI: 10.3389/fgene.2022.853113] [Reference Citation Analysis]
24 Dai H, Abdullah R, Wu X, Li F, Ma Y, Lu A, Zhang G. Pancreatic Cancer: Nucleic Acid Drug Discovery and Targeted Therapy. Front Cell Dev Biol 2022;10:855474. [PMID: 35652096 DOI: 10.3389/fcell.2022.855474] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
25 Song W, Liu Z, Wang K, Tan K, Zhao A, Li X, Yuan Y, Yang Z. Pyroptosis-related genes regulate proliferation and invasion of pancreatic cancer and serve as the prognostic signature for modeling patient survival. Discov Oncol 2022;13:39. [PMID: 35633405 DOI: 10.1007/s12672-022-00495-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
26 Ma S, Wang F, Wang N, Jin J, Ba Y, Ji H, Du J, Hu S. Multiomics Data Analysis and Identification of Immune-Related Prognostic Signatures With Potential Implications in Prognosis and Immune Checkpoint Blockade Therapy of Glioblastoma. Front Neurol 2022;13:886913. [DOI: 10.3389/fneur.2022.886913] [Reference Citation Analysis]
27 Wei J, Hui A. The Paradigm Shift in Treatment from Covid-19 to Oncology with mRNA Vaccines. Cancer Treatment Reviews 2022. [DOI: 10.1016/j.ctrv.2022.102405] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
28 Huang X, Zhang G, Liang T. Subtyping for pancreatic cancer precision therapy. Trends in Pharmacological Sciences 2022. [DOI: 10.1016/j.tips.2022.03.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Lin H, Wang K, Xiong Y, Zhou L, Yang Y, Chen S, Xu P, Zhou Y, Mao R, Lv G, Wang P, Zhou D. Identification of Tumor Antigens and Immune Subtypes of Glioblastoma for mRNA Vaccine Development. Front Immunol 2022;13:773264. [PMID: 35185876 DOI: 10.3389/fimmu.2022.773264] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
30 Tang T, Huang X, Zhang G, Lu M, Hong Z, Wang M, Huang J, Zhi X, Liang T. Oncolytic peptide LTX-315 induces anti-pancreatic cancer immunity by targeting the ATP11B-PD-L1 axis. J Immunother Cancer 2022;10:e004129. [PMID: 35288467 DOI: 10.1136/jitc-2021-004129] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Xu R, Lu T, Zhao J, Wang J, Peng B, Zhang L. Identification of Tumor Antigens and Immune Subtypes in Lung Adenocarcinoma for mRNA Vaccine Development. Front Cell Dev Biol 2022;10:815596. [PMID: 35265614 DOI: 10.3389/fcell.2022.815596] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Sun L, Zhang J, Wen K, Huang S, Li D, Xu Y, Wu J. The Prognostic Value of Lysine Acetylation Regulators in Hepatocellular Carcinoma. Front Mol Biosci 2022;9:840412. [DOI: 10.3389/fmolb.2022.840412] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
33 Zhang J, Wang N, Wu J, Gao X, Zhao H, Liu Z, Yan X, Dong J, Wang F, Ba Y, Ma S, Jin J, Du J, Ji H, Hu S. 5-Methylcytosine Related LncRNAs Reveal Immune Characteristics, Predict Prognosis and Oncology Treatment Outcome in Lower-Grade Gliomas. Front Immunol 2022;13:844778. [DOI: 10.3389/fimmu.2022.844778] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
34 Wang M, Hu Q, Huang J, Zhao X, Shao S, Zhang F, Yao Z, Ping Y, Liang T. Engineered a dual-targeting biomimetic nanomedicine for pancreatic cancer chemoimmunotherapy. J Nanobiotechnology 2022;20:85. [PMID: 35177078 DOI: 10.1186/s12951-022-01282-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
35 Sheyi R, de la Torre BG, Albericio F. Linkers: An Assurance for Controlled Delivery of Antibody-Drug Conjugate. Pharmaceutics 2022;14:396. [DOI: 10.3390/pharmaceutics14020396] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
36 Lin J, Lai X, Liu X, Yan H, Wu C. Pyroptosis in glioblastoma: A crucial regulator of the tumour immune microenvironment and a predictor of prognosis. J Cell Mol Med 2022. [PMID: 35083859 DOI: 10.1111/jcmm.17200] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Ye Z, Liu D, Liu D, Lv Y, Zhang Y, Zhang J, Bao J, Yuan X, Hou J, Li L. Immune Infiltration of CD8+ T Cells in Patients With Diabetic Pancreatic Cancer Reduces the Malignancy of Cancer Tissues: An In Silico Study. Front Endocrinol 2022;12:826667. [DOI: 10.3389/fendo.2021.826667] [Reference Citation Analysis]
38 Wu C, Duan Y, Gong S, Osterhoff G, Kallendrusch S, Schopow N. Identification of Tumor Antigens and Immune Subtypes for the Development of mRNA Vaccines and Individualized Immunotherapy in Soft Tissue Sarcoma. Cancers 2022;14:448. [DOI: 10.3390/cancers14020448] [Reference Citation Analysis]
39 Hu J, Mo Z. Dissection of tumor antigens and immune landscape in clear cell renal cell carcinoma: Preconditions for development and precision medicine of mRNA vaccine. MBE 2022;20:2157-2182. [DOI: 10.3934/mbe.2023100] [Reference Citation Analysis]
40 Li X, Wei Z, Yu H, Xu Y, He W, Zhou X, Gou X. Secretory autophagy-induced bladder tumour-derived extracellular vesicle secretion promotes angiogenesis by activating the TPX2-mediated phosphorylation of the AURKA-PI3K-AKT axis. Cancer Lett 2021;523:10-28. [PMID: 34597712 DOI: 10.1016/j.canlet.2021.09.036] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
41 Wang Y, Tan H, Yu T, Chen X, Jing F, Shi H. Potential Immune Biomarker Candidates and Immune Subtypes of Lung Adenocarcinoma for Developing mRNA Vaccines. Front Immunol 2021;12:755401. [DOI: 10.3389/fimmu.2021.755401] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
42 Ma S, Ba Y, Ji H, Wang F, Du J, Hu S. Recognition of Tumor-Associated Antigens and Immune Subtypes in Glioma for mRNA Vaccine Development. Front Immunol 2021;12:738435. [PMID: 34603319 DOI: 10.3389/fimmu.2021.738435] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
43 Zhong H, Liu S, Cao F, Zhao Y, Zhou J, Tang F, Peng Z, Li Y, Xu S, Wang C, Yang G, Li ZQ. Dissecting Tumor Antigens and Immune Subtypes of Glioma to Develop mRNA Vaccine. Front Immunol 2021;12:709986. [PMID: 34512630 DOI: 10.3389/fimmu.2021.709986] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
44 Ye L, Wang L, Yang J, Hu P, Zhang C, Tong S, Liu Z, Tian D. Identification of tumor antigens and immune subtypes in lower grade gliomas for mRNA vaccine development. J Transl Med 2021;19:352. [PMID: 34404444 DOI: 10.1186/s12967-021-03014-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
45 Zhang S, Xiong Y, Kang S, Mao C, Wang Y, Zeng Z, Peng J, Ouyang Y. Based on the identification of tumor antigens and immune subtypes in renal clear cell carcinoma for mRNA vaccine development.. [DOI: 10.1101/2021.07.04.451033] [Reference Citation Analysis]
46 Zheng Q, Yang Q, Zhou J, Gu X, Zhou H, Dong X, Zhu H, Chen Z. Immune signature-based hepatocellular carcinoma subtypes may provide novel insights into therapy and prognosis predictions. Cancer Cell Int 2021;21:330. [PMID: 34193146 DOI: 10.1186/s12935-021-02033-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
47 Huang X, Zhang G, Liang T. Cancer environmental immunotherapy: starving tumor cell to death by targeting TGFB on immune cell. J Immunother Cancer 2021;9:e002823. [PMID: 34145032 DOI: 10.1136/jitc-2021-002823] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]